Results: rhCD137L-MSNs were of higher potency than ure-MSNs or unconjugated urelumab in inducing in vitro T cell killing of the NPC cell lines C666 and HK-1, of both CD137-expressing and -deficient phenotypes. The gene discussed is TNFRSF9; the disease is nasopharyngeal carcinoma.